anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a traditional Chinese medicine, and concretely relates to an alcohol effect dispelling and liver protecting medicine. A problem that alcohol harms the health of human bodies is solved in the invention. The medicine is composed of 30 parts of pueraria flower, 50 parts of Hovenia acerba Lindl., 15 parts of dried orange peel, 15 parts of gynostemma pentaphylla and 20 parts of licorice root. A preparation method of the medicine comprises the following steps: extracting the above traditional Chinese medicines with alcohol for 24h two times, and filtering to obtain an alcohol extract liquid; respectively decocting the above obtained filter residues with water having an amount 15 times the amount of the residues and water having an amount 10 times the amount of the residues for 1.5h, and filtering to obtain a water decoction liquid; and mixing the alcohol extract liquid with the water decoction liquid, and carrying out 70DEG C reduced pressure concentration of the obtained liquid mixture to a paste (1.2-1.3g/mL). The above alcohol effect dispelling agent based on pueraria flower, Hovenia acerba Lindl., dried orange peel, licorice root and gynostemma pentaphylla has good alcohol effect dispelling and intoxication preventing effects, and can effectively reduce the concentration of ethanol in blood. Results of pharmacodynamic experiments of the medicine on mice show that if the alcohol effect dispelling agent is administrated by the mice 20min before and after wine drinking, the intoxication rate is low, the tolerance time is long before intoxication, and the maintenance time after the intoxication is short.
BACKGROUND: Ovarian cancer (OC) is a frequent malignancy of the female reproductive system. Recently, the aberrant expression of numerous lncRNAs has been confirmed as a key factor for cancer development. The regulatory role of PAX8-AS1 in some cancers has been investigated, but its role in OC progression remains unclear. This study focuses on the role and molecular mechanism of PAX8-AS1 in the malignant progression of OC.
METHODS: Bioinformatics means were adopted to analyze the expression of PAX8-AS1, microRNA-25-3p, and LATS2 in OC tissues and the binding sites between the three. qRT-PCR was employed to determine the expression of these genes in OC cells. CCK-8, colony formation, scratch healing, and Transwell assays were used to see cell viability, proliferation, migration, and invasion, respectively. Fluorescence in situ Hybridization was performed to probe the subcellular localization of PAX8-AS1. Western blot was applied to evaluate the expression and phosphorylation levels of YAP and TAZ, and an immunofluorescence assay was used to detect the translocation of them. Dual luciferase assay was applied to validate the binding relationship between PAX8-AS1 and microRNA-25-3p, as well as between microRNA-25-3p and LATS2.
RESULTS: PAX8-AS1 and LATS2 were lowly expressed. MicroRNA-25-3p was highly expressed in OC. PAX8-AS1 was expressed in cytoplasm and regulated LATS2 expression by sponging microRNA-25-3p. Overexpressing PAX8-AS1 can suppress the malignant behaviors of OC cells, whereas treatment with microRNA-mimic can reverse these results. In addition, the phosphorylation levels of YAP and TAZ increased upon oe-LATS2 treatment, and oe-LATS2 could promote YAP and TAZ translocate from the nucleus to cytoplasm. Rescue experiments demonstrated that sh-PAX8-AS1 fostered malignant progression of OC, which was reversed by simultaneous oe-LATS2.
CONCLUSION: In summary, PAX8-AS1/microRNA-25-3p/LATS2 regulated the malignant progression of OC through Hippo signaling, which suggested that PAX8-AS1/microRNA-25-3p/LATS2 axis may be a novel target for OC treatment.
Participants will be taught the home exercise program face to face. Exercises will start with diaphragmatic breathing. Breathing exercises will be done in 2 sets of 10 repetitions. Lower extremity joint range of motion exercises; It will consist of hip flexion in the supine position, hip abduction in the side lying position, hip extension and knee flexion in the prone position, knee extension and ankle dorsi-plantar flexion in the sitting position. Exercises will be increased to 3 sets of 10 repetitions for the first 3 weeks, and 3 sets of 15 repetitions after the 3rd week. After the exercises, they will be asked to walk for 20 minutes at moderate intensity on a flat surface. Additionally, the control group will be asked to walk at moderate intensity.
The invention provides lactation promoting, liver nourishing and qi and blood benefiting tea and a making technology thereof, and belongs to the field of traditional Chinese medicine. The lactation promoting, liver nourishing and qi and blood benefiting tea is made by decocting or brewing medicinal ingredients with water, wherein the medicinal ingredients comprise, by weight, 15-25 parts of Chinese yam rhizomes, 15-25 parts of radix ophiopogonis, 10-20 parts of red dates and 10-20 parts of green papayas. The lactation promoting, liver nourishing and qi and blood benefiting tea made by mixing and decocting or brewing Chinese yam rhizomes, radix ophiopogonis, red dates and green papayas can nourish yin and tonify yang, nourish blood and replenish the blood, stimulate mammin to be beneficial for promoting lactation and greatly improve the conditions that a puerperal is insufficient in milk after childbirth, is suffered from palpitation and dizziness and the like. In addition, the invention further provides the making technology of the lactation promoting, liver nourishing and qi and blood benefiting tea. The making technology comprises the steps that after the medicinal ingredients are decocted or brewed by adding the water, medicinal residues are filtered, and filtrate is taken. The making technology is simple and easy to operate, the effective ingredients of the four herbs are fully dissolved into the made lactation promoting, liver nourishing and qi and blood benefiting tea, and the treatment effect is good.
The method of nanocrystal preparation is based on the procedure of the crystalline nanoparticles preparation in powder form that comprises a) dissolving the protonated nitrogen containing derivatives of camptothecin and curcuminoids in an organic solvent leading to formation of self-assembled ionic complex followed by subsequent addition of nonionogenic injectable surfactant, b) transferring the obtained mixture into aqueous medium under continuous homogenization including mixing, shaking and/or using ultrasound, c) removing the solvent in order to obtain powder form, d) lyophilisation of the product with the previously added cryoprotectant. Composition for nanocrystal preparation through the method according to the invention consists of injectable nonionic surfactant and self-assembled ionic complex that contains curcuminoids and protonated nitrogen containing derivatives of camptothecin and its analogues in the molar ratios in the range between 10:1 and 1:10. Analogues of camptothecin include preferably camptothecin and homocamptothecin. Protonated nitrogen containing camptothecin derivatives preferably have the protonated nitrogen included in their chemical structure through at least one functional group including primary amine, secondary amine, tertiary amine, cyclic amine and/or their combinations. Utilization of nanocrystals prepared for the anticancer injectable drug application consists in the dissolution of 3 wt. % nanocrystals in powder form in the liquid medium based on distilled water with 5 wt. % of glucose.
The invention belongs to a traditional Chinese medicine composition, and particularly relates to a medicine for treating anaemia. Raw materials for preparing effective components of the medicine comprise, by weight, 25-35 g of herba agrimoniae, 15-25 g of caulis spatholobi, 15-25 g of radix astragali, 10-20 g of fructus ligustri lucidi, 10-20 g of raspberry, 10-18 g of angelica sinensis, 10-18 g of radix rehmanniae preparata, 10-18 g of herba epimedii, 10-18 g of psoralea corylifolia, 5-15 g of morinda officinalis and 5-15 g of donkey-hide gelatin. Traditional Chinese medicines are selected as raw materials of the medicine composition. The medicine composition has no toxic or side effect, takes advantages of comprehensive effects of the traditional Chinese medicines, can make qi and blood harmonious by tonifying qi and replenishing blood, and can make kidney qi adequate by nourishing and tonifying the kidney. Essence in the kidney can be converted into blood. The medicines are compatible and can complement each other. The medicine has high purity degree, is low in cost and simple in prescription, and can treat anaemia effectively.
Disclosed is a process for preparing compounds having a straight or branched aliphatic hydrocarbon structure of formula I: ##STR1## In formula I, n is an integer from one to four and m is an integer from four to twenty. Independently, R 1  and R 2  are hydrogen, a straight or branched chain alkyl, alkenyl or alkynyl of up to twenty carbon atoms in length or --(CH 2 ) w  R 5 . If R 1  or R 2  is --(CH 2 ) w  R 5 , w may be an integer from one to twenty and R 5  may be an hydroxyl, halo, C 1-8  alkoxyl group or a substituted or unsubstituted carbocycle or heterocycle. Alternatively, R 1  and R 2  may jointly form a substituted or unsubstituted, saturated or unsaturated heterocycle having from four to eight carbon atoms, N being a hetero atom of the resulting heterocyle. R 3  may be either hydrogen or C 1-3 . In the compounds, a total sum of carbon atoms comprising R 1  or R 2 , (CH 2 ) n  and (CH 2 ) m  does not exceed forty. R 4  is a terminal moiety comprising a substituted or unsubstituted, oxidized or reduced ring system, the ring system having a single ring or two to three fused rings, a ring comprising from three to seven ring atoms. The disclosed compounds are effective agents to inhibit undesirable responses to cell stimuli.
Psoriatic arthritis is a multi-faceted disease that impacts the joints, soft tissues, and skin, all of which not only results in functional disability and impaired quality of life, but participants with this disease also have increased mortality. Guselkumab is a monoclonal antibody that binds to human interleukin 23 (IL-23) and inhibits IL-23 specific intracellular signaling and subsequent activation and cytokine production. Investigation of guselkumab in this Phase 3b PsA clinical study is supported by the favorable efficacy and safety results from Phase 2 study of guselkumab in PsA and Phase 2 and Phase 3 studies in psoriasis including the subset of participants with PsA. The primary hypothesis is that guselkumab 100 milligram (mg) at Weeks 0, 4, and every 8 weeks (q8w) thereafter is superior to placebo which will be assessed by the proportion of participants achieving an American College of Rheumatology (ACR 20) response at Week 24. The study includes 2 periods: A 24-week double-blind, placebo-controlled period for the primary analysis of the efficacy and safety of guselkumab, compared with placebo and a 32-week active-treatment and safety follow-up period for additional analysis of the efficacy and safety of guselkumab. Safety will be monitored throughout the study (Up to Week 56).
Pain is one of the most common concerns among chronically ill older adults. However, access to pain management is not equitable among certain populations, including rural residents. This qualitative study explored rural older adults' experiences with pain and its treatment. Eighteen participants were recruited from rural counties of Alabama, who were age 60+, cognitively intact, community-dwelling, had one or more chronic/serious illnesses, and experienced pain. Open-ended questions were asked in individual interviews, and inductive, thematic analysis was used for data analysis. Findings revealed the impact of pain (physical limitations, psychological distress, and coping strategies), the impact of COVID-19 (physical/mental health and pain management), challenges in pain management in rural areas (lack of provider and healthcare resources, transportation-related issues, mistrust, and limited insurance coverage) and suggestions to address these challenges. Program and policy-level interventions are crucial in improving the resources and education/training needed for effective pain management for rural older adults.
OBJECTIVES: I. Determine the maximum tolerated dose (MTD) of suramin followed by doxorubicin in patients with advanced solid tumors. II. Describe the toxic effects of suramin with sequential doses of doxorubicin in these patients. III. Assess the development of peripheral neuropathy in patients with this treatment. IV. Assess the preliminary evidence of the antitumor effect of this regimen in these patients. VI. Explore the relationships between the pharmacokinetic parameters and potential neurotoxicity of suramin in these patients.

OUTLINE: This is a dose-escalation study of doxorubicin. Patients receive suramin IV daily over 1-2 hours on days 1-4 followed by doxorubicin IV over 10-15 minutes on day 5. Treatment repeats every 4 weeks for up to 3 courses in the absence of unacceptable toxicity, disease progression, or clinical deterioration. Starting from course 4, patients receive alternating courses of doxorubicin IV on day 1 every 4 weeks (courses 4, 6, 8, etc.) and suramin with doxorubicin (courses 5, 7, 9 etc.) as described above. Cohorts of 3-6 patients receive escalating doses of doxorubicin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 or more of 6 patients experience dose-limiting toxicity. Stable patients who achieve disease response and are able to receive a target cumulative dose of doxorubicin may discontinue doxorubicin and receive suramin alone every 8 weeks. Patients are followed at 3 months.

PROJECTED ACCRUAL: A maximum of 20 patients will be accrued for this study within 1 year.
The invention discloses a medicine for treating liver cancer and a preparation method thereof. The medicine is prepared from active ingredients or prepared from active ingredients and a carrier, wherein the active ingredients include curcuminoid and d-borneol. According to different dosage forms, the medicine is prepared by mixing d-borneol, curcuminoid and the carrier according to preparation methods of different dosage forms. Sustained-release tablets are prepared by firstly releasing d-borneol and then releasing curcuminoid, thereby being more favorable for absorbing and utilizing curcuminoid. After the medicine acts on the liver cancer cell HepG2, the cell can be effectively induced to generate G2/M cell cycle arrest to cause cell apoptosis, and excessive generation of ROS (reactive oxygen species) in the cell is induced to cause cell apoptosis. Therefore, the medicine provided by the invention can be used for effectively treating liver cancer, and d-borneol and curcuminoid are combined, so that the medicine has low toxicity to human normal cells and basically has no obvious effect.
This study is a dual-center, prospective, randomized controlled study to evaluate intraprocedural efficacy of anterior aspects of pulmonary veins isolation between very High Power Short Duration (vHPSD) and High Power Short Duration (HPSD) in patient with paroxysmal or persistent atrial fibrillation (AF).

Catheter ablation of atrial fibrillation with circumferential pulmonary vein isolation is an well-established method of treatment, particularly in symptomatic patients with atrial fibrillation (AF) who are ineffective or refractory to pharmacological treatment. Recurrence of pulmonary veins conduction is considered as a risk factor for future recurrence of AF. This may be partly related to the incomplete scar formation during the index ablation procedure. Constant technological progress (i.e. ablation catheters with contact force) has led to greater efficiency in obtaining complete isolation of pulmonary veins, achieving nearly 90% success rate in 12-month follow-up paroxysmal AF (CLOSE protocol). The duration of the RF application depends on the ablation index (AI), which proves that the energy has been effectively delivered to the myocardium. Currently, AI values are considered representative of RF power up to 50W. When energy above 50 W was used, the scar size was shown to be smaller than when the same AI value was used but with higher power. The safety and efficacy of novel ablation catheter QDOT (Biosense Webster, Irvine, CA, USA), that allows to deliver very high and high-power short-duration ablation, was already proven in clinical trials (QDOT FAST, Q-FFICIENCY). The benefits from using very high power short-duration ablation include: 1) shortening the duration of the procedure, 2) reducing the volume of fluids administered through the ablation electrode during RF application, which may be important in patients with heart and kidney failure, 3) reducing the frequency of collateral damages to surrounding structures of the heart (e.g. oesophagus). One of the differences related to the biophysics of RF applications between high and low energy is the range of penetration into the muscle tissue, which could impact on effectiveness of ablation. It was shown that lesions performed with vHPSD were smaller (up to 2,9 mm deep) compared to HPSD or conventional power with target AI. It is attractive for posterior wall of left atrium and can reduce peri-procedural complications. However vHPSD could be insufficient in some regions of anterior wall of the left atrium, which thickness may vary from 1 to 4 mm. Our research hypothesis is that integrated approach with different energies depending on the left atrium location is safe and lead to better efficacy than use of only vHPSD ablation in terms of first pass isolation.
PURPOSE:A novel pigment usable for cosmetics, coating materials, and printing, having improved resistance to pH and light fastness, and dispersibility, capable of assuming the original color of a coloring matter, obtained by reacting the reaction product between a clay mineral and a specific multivalent metal (or compound) with an organic coloring matter. CONSTITUTION:(A) A clay mineral, preferably treated with an alkali, containing a small amount of a peptizer, is reacted with (B) a bi- or trivalent metal (or compound), preferably an aluminum compound, e.g. aluminum hydroxide, and if necessary (C) a basicity adjustor, e.g. an alkaline (earth) metal compound, at a weight ratio of (A):(B):(C) of 5:1:1.5-1:9:20 in steam at 100-200 deg.C for 1- 10hr. The resulting product is then reacted with (D) an organic coloring matter, e.g. a tar pigment, such as Food Red No.104-1, at a weight ratio of 1:0.01-3, to give the objective pigment. EFFECT:No flocculation, aggregation, and dyeing of the skin.
Botulinum neurotoxin type A BoNT/A is used off-label as a third line therapy for neuropathic pain. However, the mechanism of action remains unclear. In recent years, the role of voltage-gated sodium channels (Nav) in neuropathic pain became evident and it was suggested that block of sodium channels by BoNT/A would contribute to its analgesic effect. We assessed sodium channel function in the presence of BoNT/A in heterologously expressed Nav1.7, Nav1.3, and the neuronal cell line ND7/23 by high throughput automated and manual patch-clamp. We used both the full protein and the isolated catalytic light chain LC/A for acute or long-term extracellular or intracellular exposure. To assess the toxin's effect in a human cellular system, we differentiated induced pluripotent stem cells (iPSC) into sensory neurons from a healthy control and a patient suffering from a hereditary neuropathic pain syndrome (inherited erythromelalgia) carrying the Nav1.7/p.Q875E-mutation and carried out multielectrode-array measurements. Both BoNT/A and the isolated catalytic light chain LC/A showed limited effects in heterologous expression systems and the neuronal cell line ND7/23. Spontaneous activity in iPSC derived sensory neurons remained unaltered upon BoNT/A exposure both in neurons from the healthy control and the mutation carrying patient. BoNT/A may not specifically be beneficial in pain syndromes linked to sodium channel variants. The favorable effects of BoNT/A in neuropathic pain are likely based on mechanisms other than sodium channel blockage and new approaches to understand BoNT/A's therapeutic effects are necessary.
The study is divided into 2 separate parts (ie, Part 1 and Part 2). Part 1 is a dose finding part (to find the optimal dose) of trabectedin for Chinese patients, and Part 2 is a multicenter, randomized (the study medication is assigned by chance), active-controlled (an active substance that is compared with the study medication to test whether the study medication has a real effect in clinical study), parallel-group (a study comparing the response in two or more groups of patients receiving different interventions), open-label (all people know the identity of the intervention) bridging part comparing the efficacy and safety of the optimal dose of trabectedin with dacarbazine in the same population as in Part 1. The study (in both Part 1 and Part 2) will consist of a screening phase, a treatment phase and a follow-up phase. Part 1: Optimal dose (ie, maximum tolerated dose \[MTD\]) is determined from the following 3 dose levels: Dose level 1 (1.5 mg/m2), Dose level 2 (1.2 mg/m2), and Dose level 3 (1.0 mg/m2)of trabectedin. Cohorts of 6 patients will be treated at each dose level. To determine MTD, dose limiting toxicity (DLT; any pre-defined adverse event that occurs during the first cycle ie, Cycle 1) will be determined. In the first cohort of 6 patients, (a) if DLT is less than or equal to 1 at a dose level, it is considered as MTD (b) if DLT is greater than 2, patients will be de-escalated to next dose level (c) if DLT is equal to 2, 3 more patients will be included at that dose level and if there will be no DLT in those 3 patients, that dose level is considered as MTD. Part 2: If the optimal dose found in Part 1 is 1.5 mg/m2, approximately 48 patients will be randomly assigned to either the trabectedin (approximately 32 patients) or dacarbazine (approximately 16 patients) treatment group in Part 2. If the optimal dose found in Part 1 is below 1.5 mg/m2, 123 patients will be randomly assigned to either the trabectedin (approximately 82 patients) or dacarbazine (approximately 41 patients) treatment group. Safety will be evaluated by assessing adverse events, clinical laboratory test, multiple gated acquisition scans, electrocardiograms, vital signs, and physical examination throughout the study up to 30 days after the end of treatment.
BACKGROUND: To explore distributed characteristics and identify research focus and emerging trends related to cancer-related fatigue (CRF) in the nursing field.
METHODS: Data were collected from the Web of Science Core Collection database between January 2012 and December 2021 using an advanced search strategy. Data were extracted and analyzed using CiteSpace and Microsoft Excel.
RESULTS: A total of 967 articles were included in this study. The number of published nursing studies on CRF has increased with slight fluctuations. Keyword co-occurrence analysis and timeline view indicated that CRF is closely related to quality of life, and there is a correlation between CRF and other symptoms. Moreover, increasing attention has been paid to CRF nursing interventions. The assessment tools and their different language versions, risk factors and reviews of CRF were the research frontiers in recent years with citation bursts.
CONCLUSIONS: In the field of nursing, the focus of CRF research is still on risk factors, adverse outcomes and nursing management. Assessment tools will continue to be developed and additional risk factors will be studied in the future.